Maxim Group Maintains Buy on Lexaria Bioscience, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Maxim Group analyst Michael Okunewitch has maintained a Buy rating on Lexaria Bioscience (NASDAQ:LEXX) and increased the price target from $3 to $12. This adjustment suggests a positive outlook on Lexaria Bioscience's future performance.
March 05, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Maxim Group analyst Michael Okunewitch has reaffirmed a Buy rating on Lexaria Bioscience and raised the price target from $3 to $12, indicating a strong positive outlook on the company's future.
The significant increase in the price target by a reputable analyst suggests a strong conviction in Lexaria Bioscience's potential for growth. This is likely to positively influence investor sentiment and potentially drive up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100